Women and Anabolic Steroids: an Analysis of a Dozen Users
Overview
Affiliations
Objective: To provide an in-depth analysis of 12 female self-reported anabolic-androgenic steroid (AAS) users.
Design: Web-based survey.
Setting: A Web-based survey was posted on 38 discussion boards of various fitness, bodybuilding, weightlifting, and steroid Web sites between February and June 2009.
Interventions: Participants completed a survey regarding demographics and use of AAS and other performance-enhancing agents (PEAs).
Participants: A cohort of 1519 strength-trained subjects fully completed and submitted a valid survey. Five hundred eighteen subjects were self-reported AAS users consisting of 12 women and 506 men. One thousand one subjects were non-AAS users consisting of 230 women and 771 men.
Main Outcome Measures: Demographic data and use of AAS and other PEAs.
Results: The female AAS users reported using an average of 8.8 PEAs in their routine. Compared with male AAS users and female non-AAS users, respectively, female AAS users were more likely to have met criteria for substance-dependence disorder (58.3% vs 23.4%; P = 0.01; 58.3% vs 9.1%; P < 0.001), have been diagnosed with a psychiatric illness (50.0% vs 17.4%; P = 0.01; 50.0% vs 22.2%; P = 0.04), and have reported a history of sexual abuse (41.7% vs 6.1%; P < 0.001; 41.7% vs 15.3%; P = 0.03).
Conclusions: Female AAS users practice polypharmacy. Female AAS users are more likely to have qualified for substance-dependence disorder, have been diagnosed with a psychiatric illness, and have a history of sexual abuse than both male AAS users and female non-AAS users.
Santos B, de Souza J, de Paula Goulart L, Petrine J, Alves F, Del Bianco-Borges B Saudi Pharm J. 2024; 32(12):102205.
PMID: 39697477 PMC: 11653648. DOI: 10.1016/j.jsps.2024.102205.
Skrzypiec-Spring M, Rozmus J, Abu Faraj G, Brawanska-Masluch K, Kujawa K, Szelag A J Clin Med. 2024; 13(19).
PMID: 39407952 PMC: 11478083. DOI: 10.3390/jcm13195892.
The sexual impact of androgenic anabolic steroid abuse an understudied phenomena.
Akula K, McBeth L, Hofer M Int J Impot Res. 2024; 37(2):114-115.
PMID: 38594389 DOI: 10.1038/s41443-024-00879-6.
Hoseini R, Hoseini Z BMC Public Health. 2024; 24(1):798.
PMID: 38481173 PMC: 10938795. DOI: 10.1186/s12889-024-18292-5.
Garcia J, Seco-Calvo J, Arribalzaga S, Diez R, Lopez C, Fernandez M Front Pharmacol. 2023; 14:1305080.
PMID: 38111382 PMC: 10725911. DOI: 10.3389/fphar.2023.1305080.